



May 10, 2021

BSE Limited

Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

**Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations
and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

Enclosed is a Press Release as regards the Company signing a royalty-free, limited, non-exclusive voluntary licensing agreement with Eli Lilly and Company (Lilly) for manufacturing and selling of Lilly's drug Baricitinib in India.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

FOR LUPIN LIMITED

**R. V. SATAM
COMPANY SECRETARY
(ACS-1 1973)**

Encl- : a/a.

Lupin enters into Voluntary Licensing Agreement with Lilly to Expand Access for COVID-19 Treatment in India

Mumbai, India, May 10, 2021: Global pharma major, Lupin Limited (Lupin) today announced that it has signed a royalty-free, limited, non-exclusive voluntary licensing agreement with Eli Lilly and Company (Lilly) for manufacturing and selling of Lilly's drug Baricitinib in India.

Lilly has received permission from Central Drugs Standard Control Organization (CDSCO), Ministry of Health, for restricted emergency use of Baricitinib in combination with Remdesivir for the treatment of suspect or laboratory-confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.

With a rapid increase in active COVID-19 cases in India, the timely restricted emergency use of Baricitinib will be an important life-saving treatment for patients with moderate to severe symptoms of COVID-19.

About Lupin Limited

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. For the nine months ended December 31, 2020, the Company invested 9.8% of its revenues on research and development.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: <https://twitter.com/LupinGlobal> | LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

About Eli Lilly India

Eli Lilly and Company (India) Pvt. Ltd. (Lilly India), headquartered in Gurgaon, is a wholly owned subsidiary of Eli Lilly and Company, a global biopharmaceutical company headquartered in Indianapolis, USA. Since its



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

inception more than 25 years ago, Lilly India has been committed to offer advanced treatment options to treat chronic diseases such as diabetes, lung cancer, gastric cancer, osteoporosis, rheumatoid arthritis, men's health and growth-hormone deficiency. To learn more about Lilly India, please visit us at <https://www.lillyindia.co.in>; [Facebook](#); [LinkedIn](#)

For further information or queries please contact –

Shweta Munjal Head – Corporate Communications Email: shwetamunjal@lupin.com	Arvind Bothra Head – Investor Relations/Corporate M&A Email: arvindbothra@lupin.com	Manjira Sharma General Manager – Corporate Communications Email: manjirasharma@lupin.com
--	--	--